ClearPoint Neuro Q1 2026 Earnings EPS Misses Estimates Despite Positive Stock Movement EXFY Q1 2026 Earnings EPS Beats Estimates by 68 as Cost Discipline Drives Profitability SLSN Q1 2026 Earnings Narrowed Loss Amidst Operational Uncertainty XOMA Q1 2026 Earnings Royalty Revenue Challenges Lead to EPS Miss Stock Slips IMRX Q1 2026 Earnings EPS Beat Estimates by 183 as Clinical Pipeline Advances CURI Q1 2026 Earnings EPS Miss Amid Subscriber Challenges